Flagship Ventures Fund IV-Rx, L.P. insider trades: Evelo Biosciences (EVLO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Flagship Ventures Fund IV-Rx, L.P. reports to the SEC
and 2 more companies
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 27, 2022 | EVLO | ↑ Buy | 13,698,630 | $1.46 | $20.0M | By Flagship Pioneering Fund VII, L.P. | Jun 1, 2022 (5d) |
| May 27, 2022 | EVLO | ↑ Buy | 6,849,315 | $1.46 | $10.0M | By Nutritional Health LTP Fund, L.P. | Jun 1, 2022 (5d) |
| May 27, 2022 | EVLO | ↑ Buy | 4,383,561 | $1.46 | $6.4M | By Flagship Ventures Fund IV, L.P. | Jun 1, 2022 (5d) |
| May 27, 2022 | EVLO | ↑ Buy | 1,369,863 | $1.46 | $2.0M | By Flagship Ventures Opportunities Fund | Jun 1, 2022 (5d) |
| May 27, 2022 | EVLO | ↑ Buy | 1,095,890 | $1.46 | $1.6M | By Flagship Ventures Fund IV-Rx, L.P. | Jun 1, 2022 (5d) |
| Mar 16, 2022 | AXLA | ↑ Buy | 3,791,623 | $1.91 | $7.2M | By Flagship Ventures Fund IV, L.P. | Mar 18, 2022 (2d) |
| Mar 16, 2022 | AXLA | ↑ Buy | 1,579,843 | $1.91 | $3.0M | By Flagship Ventures Opportunities I, L. | Mar 18, 2022 (2d) |
| Mar 16, 2022 | AXLA | ↑ Buy | 947,905 | $1.91 | $1.8M | By Flagship Ventures Fund IV-Rx, L.P. | Mar 18, 2022 (2d) |
| Feb 2, 2021 | EVLO | ↑ Buy | 130,000 | $15.00 | $1.9M | Indirect | Feb 4, 2021 (2d) |
| Jun 29, 2020 | EVLO | ↑ Buy | 4,666,666 | $3.75 | $17.5M | Indirect | Jul 1, 2020 (2d) |
| May 22, 2020 | MRNA | ↓ Sell | 1,000,000 | $68.22 | $68.2M | Indirect | May 26, 2020 (4d) |
| May 18, 2020 | AXLA | ↑ Buy | 3,800,000 | $4.75 | $18.1M | Indirect | May 20, 2020 (2d) |
| Dec 11, 2019 | MRNA | ↓ Sell | 435,855 | $18.81 | $8.2M | Indirect | Dec 11, 2019 (0d) |
| May 13, 2019 | AXLA | ↑ Buy | 500,000 | $20.00 | $10.0M | Indirect | May 15, 2019 (2d) |
| May 11, 2018 | EVLO | ↑ Buy | 281,250 | $16.00 | $4.5M | Indirect | May 15, 2018 (4d) |
| Sep 23, 2016 | EBIO | ↓ Sell | 443,422 | $3.16 | $1.4M | Direct | Sep 26, 2016 (3d) |
| Sep 21, 2016 | EBIO | ↓ Sell | 386,340 | $3.69 | $1.4M | Direct | Sep 21, 2016 (0d) |
| Sep 15, 2016 | EBIO | ↓ Sell | 46,692 | $4.18 | $195K | Direct | Sep 16, 2016 (1d) |
| Sep 7, 2016 | EBIO | ↓ Sell | 129,497 | $4.54 | $588K | Direct | Sep 8, 2016 (1d) |
| Jul 6, 2016 | SYRS | ↑ Buy | 400,000 | $12.50 | $5.0M | Indirect | Jul 7, 2016 (1d) |
| May 25, 2016 | MCRB | ↓ Sell | 1,000,000 | $27.60 | $27.6M | Indirect | May 27, 2016 (2d) |
| Feb 11, 2014 | EBIO | ↑ Buy | 378,729 | $10.00 | $3.8M | Direct | Feb 13, 2014 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Flagship Ventures Fund IV-Rx, L.P.'s insider trades
Flagship Ventures Fund IV-Rx, L.P. is a 10% owner of Evelo Biosciences (EVLO). Since Feb 11, 2014, it has reported 15 open-market purchases worth $112.9M and 7 sales worth $107.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (8 filings), other transactions (7 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EVLO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.